Forum Topic News
  • Conversation: Carrick licenses targeted ovarian cancer drug from BTG

    • October 11, 2018 4:19 PM BST
    • Carrick licenses targeted ovarian cancer drug from BTG

      Dublin, Ireland-based biopharma Carrick Therapeutics has licensed exclusive globl rights to develop and commercialise BTG’s targeted ovarian cancer drug BTG945.
      The investigational drug, a combination of the targeting folate receptor α (FRα) and inhibiting thymidylate synthase, will now be referred to as CT900.
      The small molecule compound – discovered by the Institute of Cancer Research - selectively enters cancer cells that over express folate receptor α (FRα) versus normal tissues and inhibits thymidylate synthase, leading to cell death.
      Read more: http://www.pharmatimes.com/news/carrick_licenses_targeted_ovarian_cancer_drug_from_btg_1255359

Add Reputation

Do you want to add reputation for this member by this post?

or cancel